FutureFuel experienced a 56% drop in revenue year-over-year for Q3 2025, driven by weakness in its biofuel segment due to regulatory uncertainty. The company posted a net loss of $9.3 million and negative adjusted EBITDA. However, it continues to invest in plant reliability and new chemical capacity to support future growth.

FutureFuel posted Q2 2025 revenue of $35.673M, down 51% YoY, due to challenging biodiesel market conditions and high feedstock prices. The company recorded a net loss of $10.416M, an operating loss of $11.928M, and negative adjusted EBITDA of $9.823M. Chemical segment revenue was $16.619M, while biofuel revenue fell sharply to $19.054M. Capital expenditures rose to $9.478M for the quarter.

FutureFuel experienced a significant decline in financial performance in Q1 2025, with revenues decreasing by 70% and a shift from net income to a substantial net loss, primarily due to lower biofuel volumes from an extended plant turnaround and challenging market conditions.

FutureFuel Corp. announced a significant decline in financial results for the fourth quarter of 2024, with revenues decreasing by 33% to $61.5 million and net income falling by 88% to $2.8 million. This downturn was largely attributed to reduced volumes and prices in the biofuel segment, alongside operational challenges including plant downtime for turnaround maintenance.

FutureFuel Corp. reported a decrease in revenues and a net loss for the third quarter of 2024, primarily due to lower sales volumes and prices in the biofuel segment, and margin pressure in the chemical segment.

FutureFuel Corp. reported a net income of $9.6 million for Q2 2024, a significant improvement from the net loss of $9.9 million in Q2 2023. The company's performance reflects a recovering chemical industry and a competitive biofuels market. The sale of separated RINs and a reduced RIN inventory contributed significantly to the improved earnings.

FutureFuel Corp. reported weaker second-quarter results due to the timing of separated RIN sales, which were held in inventory and sold in July. The chemical segment continued to grow with improved margins.